Search
Immunology_Inflammation.pdf
Immunology_Flyer_BIO-2021.pdf
Animal Health Partnering Interests Immunology & Inflammation May 2024 CORP
Partnering in Immunology & Inflammation MAY 2024 CORP_0.pdf
Partnering in Immunology & Resp MAY 2024 CORP.pdf
Horses
Horses
Unmet needs in Generalized Pustular Psoriasis (GPP)
Live well with Generalized Pustular Psoriasis (GPP)
Generalised-Pustular-Psoriasis-Infographic
What is GPP? GPP is a rare and chronic autoinflammatory skin disease with recurrent episodes of exacerbations or flares
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
SIRPα antagonist
SIRPα antagonist
GPP
GPP
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager: DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
CD137/FAP agonist
CD137/FAP agonist
B7-H6/CD3 T-Cell Engager
B7-H6/CD3 T-Cell Engager
KISIMA® cancer vaccine
KISIMA® Cancer Vaccine
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
VSV-GP
VSV-GP
Targeting Tumor Stroma
Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
Advancing health: Our impactful R&D investments
Discover how we’re investing in sustainable impact with an unwavering commitment to research and development
Spotlight on GPP
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.